Summit Therapeutics Inc logo

Summit Therapeutics Inc

$ 1.22 +0.02 (+1.67%) 10:08 PM EST
P/E:
At Loss
P/B:
2.33
Market Cap:
$ 245.48M
Enterprise V:
$ 215.47M
Volume:
393.52K
Avg Vol (2M):
2.88M
Also Trade In:
Volume:
393.52K
Market Cap $:
245.48M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.88M
Enterprise Value $:
215.47M
PB Ratio:
2.33
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Name Current Vs Industry Vs History
Cash-To-Debt 2.1
Equity-to-Asset 0.54
Debt-to-Equity 0.53
Debt-to-EBITDA -0.33
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.7
Distress
Grey
Safe
Beneish M-Score -1.98
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 42.88
9-Day RSI 47.29
14-Day RSI 49.58
6-1 Month Momentum % -49.67
12-1 Month Momentum % -71.56

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.23
Quick Ratio 5.23
Cash Ratio 3.78
Days Sales Outstanding 211.15

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -88.2

Financials (Next Earnings Date:2022-11-15 Est.)

SMMT's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SMMT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.045
EPS (TTM) ($) -0.87
Beta 0.69
Volatility % 76.79
14-Day RSI 49.58
14-Day ATR ($) 0.143109
20-Day SMA ($) 1.249
12-1 Month Momentum % -71.56
52-Week Range ($) 0.8801 - 5.79
Shares Outstanding (Mil) 201.22

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Summit Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Summit Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.